Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 8/20 | 0.51 |
| ▸ | RAF1 | P04049 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 5/20 | 0.36 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24956799 | 1.00 | MTOR (0.51) | MTORRAF1BRAFPARP1TNKS2 | |
| SCHEMBL24955553 | 0.88 | MTOR (0.49) | MTORPIK3CAPIK3R1 | |
| SCHEMBL24955554 | 0.88 | MTOR (0.49) | MTORPIK3CAPIK3R1 | |
| SCHEMBL30202081 | 0.80 | PDE10A (0.36) | MTORPIK3CA | |
| SCHEMBL24955777 | 0.80 | PDE10A (0.36) | MTORPIK3CA | |
| SCHEMBL31106956 | 0.79 | MTOR (0.56) | MTORRAF1BRAFPARP1TNKS2 | |
| SCHEMBL24955545 | 0.79 | PIK3R1 (0.42) | MTORPIK3CAPIK3R1 | |
| SCHEMBL30202402 | 0.78 | HTR2C (0.45) | MTORRAF1BRAFPIK3CAPIK3R1 | |
| SCHEMBL24954159 | 0.78 | HTR2C (0.45) | MTORRAF1BRAFPIK3CAPIK3R1 | |
| SCHEMBL24956790 | 0.77 | PIK3CA (0.42) | MTORPIK3CDPIK3CAGBA1PIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2024-10-17 | — | — | US | disclosed |
| EP-4377313-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | BenevolentAI Cambridge Limited (GB) | 2024-06-05 | — | — | EP | disclosed |
| WO-2023007185-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | Benevolentai Cambridge Limited (GB) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343729-A1 | IMIDAZOLE ORGANIC COMPOUNDS AND THEIR USE AGAINST INFLAMMATORY BOWEL DISEASE | SI, SLC10A2, NOS3 | MTOR 777/4885RAF1 3846/4885BRAF 2735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.